Azelaic Acid 15% Gel for Reduction of Inflammatory Rosacea Lesions

Skin Therapy Letter-Family Practice Edition

Paul J. Wirth¹  Meagan-Helen Henderson Berg²  Neil Sadick³ 

[1] 1University of Buffalo, Buffalo, NY, USA;2McGill University, Montreal, QC, Canada;3Department of Dermatology, Weill Medical College of Cornell University, New York, NY, USA

关键词: atopic dermatitis;    biologics;    dupilumab;    eczema;    Th2 related inflammation;   

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Approximately 16 million Americans have rosacea, an inflammatory cutaneous disorder with central facial erythema, papules, pustules, telangiectasia, flushing, and swelling being among the more commonly recognized features. Overexpression of cathelicidin peptide LL-37 has been implicated in the pathophysiology of rosacea. Azelaic acid has been found to inhibit the pathologic expression of cathelicidin, as well as the hyperactive protease activity that cleaves cathelicidin into LL-37. Given these findings, a small prospective, open-label, interventional trial was undertaken to assess the effects of azelaic acid 15% gel on inflammatory lesions of papulopustular rosacea in a real-world setting. Use of azelaic acid was associated with a significant reduction in inflammatory lesions, which persisted beyond the active treatment phase. Overall, azelaic acid 15% gel is an appropriate initial topical therapy for the treatment of moderate facial rosacea. 

【 授权许可】

CC BY